Karisa C Schreck

List of Publications by Year
in descending order

40 papers	1,546 citations	623188 14 h-index	414034 32 g-index
41 all docs	41 docs citations	41 times ranked	2774 citing authors

#	Article	IF	Citations
1	Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma. Stem Cells, 2007, 25, 2524-2533.	1.4	578
2	The exon junction complex component Magoh controls brain size by regulating neural stem cell division. Nature Neuroscience, 2010, 13, 551-558.	7.1	156
3	The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance. Clinical Cancer Research, 2010, 16, 6060-6070.	3.2	146
4	BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers, 2019, 11, 1262.	1.7	99
5	Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. Journal of Neuro-Oncology, 2019, 143, 87-93.	1.4	68
6	Notch, Neural Stem Cells, and Brain Tumors. Cold Spring Harbor Symposia on Quantitative Biology, 2008, 73, 367-375.	2.0	66
7	Notch Signaling Promotes Growth and Invasion in Uveal Melanoma. Clinical Cancer Research, 2012, 18, 654-665.	3.2	63
8	Concurrent BRAF/MEK Inhibitors in BRAF V600â€“Mutant High-Grade Primary Brain Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 343-347.	2.3	46
9	Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, 469-474.	0.6	34
10	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	3.9	34
11	Clinical response to bevacizumab in schwannomatosis. Neurology, 2014, 83, 1986-1987.	1.5	33
12	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
13	Notch3 Activation Promotes Invasive Glioma Formation in a Tissue Site-Specific Manner. Cancer Research, 2011, 71, 1115-1125.	0.4	32
14	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	0.6	23
15	Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. Clinical Cancer Research, 2021, 27, 6197-6208.	3.2	20
16	Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma. Neurology, 2021, 97, e953-e963.	1.5	18
17	Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa138.	0.4	14
18	Effect of ketogenic diets on leukocyte counts in patients with epilepsy. Nutritional Neuroscience, 2019, 22, 522-527.	1.5	12

#	Article	IF	Citations
19	A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathologica, 2013, 126, 607-608.	3.9	9
20	Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathology, 2021, 38, 228-233.	1.1	9
21	Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene, 2022, 41, 2973-2983.	2.6	9
22	Neurosarcoidosis Presenting With Recurrent Strokes. Neurohospitalist, The, 2017, 7, 91-95.	0.3	7
23	PML: a tumor suppressor essential for neocortical development. Nature Neuroscience, 2009, 12, 108-110.	7.1	6
24	Notch Signaling Activation in Pediatric Low-Grade Astrocytoma. Journal of Neuropathology and Experimental Neurology, 2015, 74, 121-131.	0.9	6
25	Cerebral Ketones Detected by 3T MR Spectroscopy in Patients with High-Grade Glioma on an Atkins-Based Diet. American Journal of Neuroradiology, 2019, 40, 1908-1915.	1.2	6
26	Clinical Reasoning: A 70-year-old woman with acute-onset weakness and progressive hemiataxia. Neurology, 2016, 87, e264-e268.	1.5	5
27	High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes. Expert Review of Anticancer Therapy, 2022, 22, 275-287.	1.1	3
28	Clinical Reasoning: A 44-year-old woman with rapidly progressive weakness and ophthalmoplegia. Neurology, 2015, 85, e22-7.	1.5	2
29	PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS. Neuro-Oncology, 2018, 20, vi164-vi164.	0.6	2
30	RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. Neuro-Oncology Practice, 2020, 7, 369-375.	1.0	2
31	Abstract 4141: Notch signaling: A new potential target in the treatment of uveal melanoma. , 2010, , .		1
32	Abstract 1415: The Notch ligand Jag 2 promotes growth and invasion in uveal melanoma cells. Cancer Research, 2011, 71, 1415-1415.	0.4	1
33	Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response.. Journal of Clinical Oncology, 2020, 38, e14506-e14506.	0.8	1
34	EXTH-39. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY. Neuro-Oncology, 2019, 21, vi90-vi90.	0.6	0
35	ACTR-44. FEASIBILITY, PHARMACODYNAMICS, AND BIOLOGIC ACTIVITY OF THE GLIOMA ATKINS-BASED DIET (GLAD) FOR PREVENTING TUMOR RECURRENCE IN GLIOMA PATIENTS. Neuro-Oncology, 2019, 21, vi23-vi23.	0.6	0
36	BIMG-23. SINGLE-VOXEL VERSUS MULTI-SLICE MRSI IN PATIENTS WITH GLIOMA ON A KETOGENIC DIET INTERVENTION. Neuro-Oncology Advances, 2021, 3, i6-i6.	0.4	0

#	Article	IF	Citations
37	DDRE-31. FEASIBILITY AND BIOLOGIC ACTIVITY OF A KETOGENIC / INTERMITTENT FASTING DIET IN GLIOMA PATIENTS. Neuro-Oncology Advances, 2021, 3, i13-i13.	0.4	0
38	ECOA-10. Integrated genomic and clinical analysis of BRAF-mutated glioma in adults. Neuro-Oncology Advances, 2021, 3, ii3-ii3.	0.4	0
39	PATH-26. INTEGRATED MOLECULAR AND CLINICAL ANALYSIS OF BRAF-MUTATED GLIOMA IN ADULTS. Neuro-Oncology, 2020, 22, ii169-ii170.	0.6	0
40	DDRE-13. DECONVOLUTING MECHANISMS OF RESISTANCE TO BRAF INHIBITORS IN BRAF V600E HUMAN GLIOMA. Neuro-Oncology, 2020, 22, ii64-ii64.	0.6	0